Topic: Lung cancer.
Destination: LCRF has launched a new funding mechanism to support research projects with a focus on characterizing, identifying, treating or overcoming/preventing resistance to therapies in tumors harboring alterations in oncogenic drivers in NSCLC cells, tissues, mouse models, or patients. Work supported through this mechanism will addresses important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. In 2022, in partnership with leading patient advocacy organizations, this grant mechanism will focus on three specific oncogenes: EGFR, MET and KRAS.
Budget: $150,000
Duration: 2 years.
Llena el siguiente formulario para recibir más información: